(NASDAQ: UTHR) United Therapeutics's forecast annual revenue growth rate of 6.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.66%.
United Therapeutics's revenue in 2024 is $2,616,700,000.On average, 7 Wall Street analysts forecast UTHR's revenue for 2024 to be $125,618,032,492, with the lowest UTHR revenue forecast at $121,435,328,054, and the highest UTHR revenue forecast at $128,775,259,814. On average, 7 Wall Street analysts forecast UTHR's revenue for 2025 to be $134,782,769,836, with the lowest UTHR revenue forecast at $121,212,827,683, and the highest UTHR revenue forecast at $143,586,372,305.
In 2026, UTHR is forecast to generate $141,054,601,935 in revenue, with the lowest revenue forecast at $122,933,568,406 and the highest revenue forecast at $158,699,579,880.